The Food and Drug Administration is forming a work group to explore whether and how to temporarily import suitable substitutes for critical drugs with only one manufacturer, and no patents or exclusivities, when price increases or supply disruptions create significant barriers to patient access, FDA Commissioner Scott Gottlieb, M.D., announced today. The work group will examine issues such as the statutory and regulatory requirements relevant to developing and advancing such a policy. In other news, the FDA yesterday released a plan to speed biosimilar products to market and final guidance on labeling for biosimilar products. The plan focuses on streamlining and clarifying the product development and approval process; educating clinicians, patients and payers about biosimilars; and reducing anticompetitive behavior. While FDA has approved 11 biosimilars, only three are currently marketed in the U.S. According to a study the agency plans to release soon, Americans would have saved more than $4.5 billion in 2017 if all approved biosimilars were on the market, Gottlieb said.

Related News Articles

Headline
Sens. Lamar Alexander, R-Tenn., and Patty Murray, D-Wash., today introduced the Lower Health Care Costs Act (S.1895), legislation to prevent surprise medical…
Headline
The Senate Committee on Health, Education, Labor and Pensions today held a hearing on the Lower Health Care Costs Act, its draft legislation to prevent…
Headline
The AHA today commended the Centers for Medicare…
Headline
In an evaluation of 49 top-selling brand-name drugs, 28 of the drugs available since 2012 saw an increase in insurer and out-of-pocket costs of more than 50…
Headline
Ways and Means Committee Chairman Richard Neal, D-Mass., and Energy and Commerce Committee Chairman Frank Pallone Jr., D-N.J., along with Ranking Members Kevin…
Headline
The Department of Health and Human Services aims to release proposed rules amending the physician self-referral (Stark law) regulations and safe-harbors under…